Drug Combination Details
General Information of the Combination (ID: C74854) | |||||
---|---|---|---|---|---|
Name | Vitamin D NP Info | + | Spironolactone Drug Info | ||
Structure |
![]() |
+ |
![]() |
||
Disease |
Skin inflammation
[ICD-11: ME66]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | CCL2 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | IL1A | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | IL1B | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MMP-9 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | NOS2 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Increase | M2/M1 ratio | ||||
In-vitro Model | RAW-Dual | CVCL_A7ZK | Mouse leukemia | Mus musculus | ||
In-vivo Model | Six- to eight-week-old C57BL/6J female mice were used in this study. | |||||
Experimental
Result(s) |
VD3 and SP may constitute an effective treatment regimen to improve wound healing after NM or other skin chemical injury. |
References | ||||
---|---|---|---|---|
Reference 1 | A novel treatment for skin repair using a combination of spironolactone and vitamin D3. Ann N Y Acad Sci. 2020 Nov;1480(1):170-182. |





